Skip to main content
Clinical Trials/NL-OMON20251
NL-OMON20251
Completed
Not Applicable

Enhancement of exposure therapy for social anxiety disorder with testosterone: A proof-of-concept randomized placebo-controlled trial

Prof. dr. Karin Roelofs-Radboud University Nijmegen, Behavioural Science Institute (BSI) & Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, Postbus 9101, 6500 HB Nijmegen-Leiden University, Faculty of Social and BehaviouralSciences, Institute of PsychologyWassenaarseweg 52, 2333 AK LeidenK.roelofs@donders.ru.nl0 sites52 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Social anxiety disorderSpeach anxietyExposure therapySociale angststoornisSpreekangstExposure behandeling
Sponsor
Prof. dr. Karin Roelofs-Radboud University Nijmegen, Behavioural Science Institute (BSI) & Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, Postbus 9101, 6500 HB Nijmegen-Leiden University, Faculty of Social and BehaviouralSciences, Institute of PsychologyWassenaarseweg 52, 2333 AK LeidenK.roelofs@donders.ru.nl
Enrollment
52
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Prof. dr. Karin Roelofs-Radboud University Nijmegen, Behavioural Science Institute (BSI) & Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, Postbus 9101, 6500 HB Nijmegen-Leiden University, Faculty of Social and BehaviouralSciences, Institute of PsychologyWassenaarseweg 52, 2333 AK LeidenK.roelofs@donders.ru.nl

Eligibility Criteria

Inclusion Criteria

  • Woman, 18\-45 years old
  • \- Social Anxiety Disorder (SAD) as established with a structured interview (MINI), and with speech anxiety as primary fear

Exclusion Criteria

  • \- Prior non response to exposure therapy (i.c. speech exposure) for SAD symptoms, as defined by the patient’s report of receiving specific and regular exposure assignments as part of previous therapy.
  • \- Entry of patients with other mood or anxiety disorders will be permitted in order to increase accrual of a clinically relevant sample; however in cases where SAD is not judged to be the predominant disorder, participants will not be eligible.

Outcomes

Primary Outcomes

Not specified

Similar Trials